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Background: Inflammatory breast cancer (IBC) is a highly angiogenic disease; thus, antiangiogenic therapy should
result in a clinical response. However, clinical trials have demonstrated only modest responses, and the reasons for
these outcomes remain unknown. Therefore, the purpose of this retrospective study was to determine the
prognostic value of protein levels of vascular endothelial growth factor (VEGF-A), one of the main targets of
antiangiogenic therapy, and its receptors (VEGF-R1 and -R2) in IBC tumor specimens.
Patients and Methods: Specimens from IBC and normal breast tissues were obtained from Algerian patients.
Tumor epithelial and stromal staining of VEGF-A, VEGF-R1, and VEGF-R2 was evaluated by immunohistochemical
analysis in tumors and normal breast tissues; this expression was correlated with clinicopathological variables and
breast cancer-specific survival (BCSS) and disease-free survival (DFS) duration.
Results: From a set of 117 IBC samples, we evaluated 103 ductal IBC tissues and 25 normal specimens. Significantly
lower epithelial VEGF-A immunostaining was found in IBC tumor cells than in normal breast tissues (P <0.01),
cytoplasmic VEGF-R1 and nuclear VEGF-R2 levels were slightly higher, and cytoplasmic VEGF-R2 levels were
significantly higher (P = 0.04). Sixty-two percent of IBC tumors had high stromal VEGF-A expression. In univariate
analysis, stromal VEGF-A levels predicted BCSS and DFS in IBC patients with estrogen receptor-positive (P <0.01 for
both), progesterone receptor-positive (P = 0.04 and P = 0.03), HER2+ (P = 0.04 and P = 0.03), and lymph node
involvement (P <0.01 for both). Strikingly, in a multivariate analysis, tumor stromal VEGF-A was identified as an
independent predictor of poor BCSS (hazard ratio [HR]: 5.0; 95% CI: 2.0-12.3; P <0.01) and DFS (HR: 4.2; 95% CI: 1.7-
10.3; P <0.01).
Conclusions: To our knowledge, this is the first study to demonstrate that tumor stromal VEGF-A expression is a
valuable prognostic indicator of BCSS and DFS at diagnosis and can therefore be used to stratify IBC patients into
low-risk and high-risk groups for death and relapses. High levels of tumor stromal VEGF-A may be useful for
identifying IBC patients who will benefit from anti-angiogenic treatment.Background
Inflammatory breast cancer (IBC) is a rare but highly ag-
gressive and lethal form of locally advanced breast can-
cer with clinical signs that mimic an inflammatory
process, such as diffuse breast erythema, peau d’orange,
skin induration, and warmth. Tumor emboli are often
identified in the dermal lymphatics, although the emboli* Correspondence: harias@salud.unm.edu
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distribution, and reproduction in any mediumare not always seen on skin biopsy [1,2]. Furthermore,
the high expression levels of angiogenic [3-6], lymphan-
giogenic [3,7], and vasculogenic mimicry factors [4,8,9]
observed in IBC specimens is considered critical to IBC’s
metastatic behavior [10,11].
Vascular endothelial growth factor-A (VEGF-A), one
of the most potent promoters of angiogenesis and lym-
phangiogenesis, is a secreted ligand with specific recep-
tors (VEGF-R1 and -R2) that are expressed principally
by angioblasts and endothelial cells; it is involved in
endothelial cell growth, motility, and blood vessel per-
meability [12,13]. Abnormal VEGF-A, VEGF-R1, andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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including IBC [3,6,14].
Given IBC’s highly angiogenic features, anti-angiogenic
agents that target VEGF-A and VEGF-R2 have been
evaluated in clinical trials [15-19]. Although complete
pathological responses have been rare, a direct inhibitory
effect on angiogenic parameters has been observed: spe-
cifically, 1) VEGF-A expression levels in tumor cells at
baseline were higher in responders than in non-
responders [16,17]; 2) patients with high VEGF-A and
PDGFR-β expression levels in tumor cells and high
CD31 expression levels in the tumor vasculature were
more likely to response from anti-angiogenic treatment
[17]; and 3) increased plasma levels of vascular cell ad-
hesion molecule-1, decreased plasma levels of E-selectin
[18], and high baseline levels of p53, HER2, and tumor
apoptosis in tumor cells were correlated with a poor
clinical response [19].
Current therapies, including bevacizumab (Avastin;
Genentech, Inc., San Francisco, CA) [15-19], have had
minimal effects on overall survival in IBC patients be-
cause of our poor knowledge of IBC’s biologic character-
istics and of its specific prognostic markers. Abnormal
mRNA VEGF levels [3,6,14] and high circulating VEGF
levels [20] are more often associated with IBC than with
non-IBC. However, the precise localization of VEGF-A
protein (epithelial tumor cells and tumor stromal com-
ponents) and its role as a prognostic marker in IBC
tumors remain unknown. Given the known role of host
factors in anti-VEGF-A resistance [21] and the stroma’s
influence on cancer phenotype and aggressiveness and
on patient outcome [22], we determined the protein ex-
pression of VEGF-A, VEGF-R1, and VEGF-R2 in a large
set of IBC cases and correlated this expression level with
known biomarkers, lymph node (LN) status, endocrine
treatment, and breast cancer-specific (BCSS) and
disease-free survival (DFS) duration.
Methods
Patients and specimens
IBC was clinically defined by a rapid onset (i.e., clinical
evolution of less than 6 months) of breast edema and
erythema, peau d’orange, warmth, and with or without
underlying mass, and a histological confirmation of inva-
sive breast carcinoma, with or without evidence of der-
mal lymphatic invasion. Tumors were histologically
graded according to the Scarff-Bloom-Richardson classi-
fication system [23]. We identified 117 patients with
stage IIIB IBC who had been treated at the Pierre et
Marie Curie Cancer Center (PMCCC) (Algiers, Algeria)
from August 2005 to March 2009. We obtained
formalin-fixed, paraffin-embedded surgical incisional bi-
opsy specimens that had been collected before any sys-
temic treatment and normal breast tissues from 25reduction mammoplasty patients. Normal breast tissue
in 16 cases was derived from reduction mammoplasties,
and normal tissue in the remaining 9 cases was taken at
least 2 cm from the primary IBC tumor. We used tissue
samples to build tissue microarrays (TMAs). In brief,
hematoxylin-stained slides were used to delineate the
tumor region on the donor block, and two 1.5-mm cores
were obtained from each tumor sample using the
advanced tissue arrayer (Millipore, Billerica, MA). The
baseline demographic and clinical-pathological informa-
tion and estrogen receptor (ER), progesterone receptor
(PR), HER2, and epidermal growth factor receptor
(EGFR) expression levels have been previously described
[24]. This observational study was performed on an-
onymous paraffin blocks and was approved by the Uni-
versity of New Mexico Cancer Center and PMCCC
Institutional Review Boards with a waiver for patient’s
consent due to the retrospective nature of the study.
Evaluation of VEGF-A, VEGF-R1, and VEGF-R2 expression
Immunohistochemical staining for VEGF-A, VEGF-R1,
and VEGF-R2 was performed using validated antibodies
prior to being performed in tumor sections, as we have
previously described [25]. In brief, 5-μm formalin-fixed,
paraffin-embedded sections were cut from tissue micro-
arrays, placed on SuperFrost/Plus slides (Fisher Scien-
tific; Fair Lawn, NJ), and dried for 1 hour at 60°C. When
only limited tumor samples existed in the two 1.5-mm
TMA cores or the core tissue had been lost during the
immunohistochemical procedure, a full face section
from the original block was used (10 cases for VEGF-R1
and 3 for VEGF-R2, or 10% and 3% of samples, respect-
ively). Sections were deparaffinized in xylene and rehy-
drated through graded alcohols to water. Antigen
retrieval (Diva solution, Biocare; Concord, CA) was per-
formed for all antibodies at 95°C for 20 minutes in a
decloaking chamber (Biocare), followed by incubation
for 20 minutes in 3% hydrogen peroxide in phosphate
buffer solution (1x; Invitrogen; Carlsbad, CA) to block
endogenous peroxidase activity. Endogenous biotin was
blocked by incubation for 10 minutes with Background
Sniper (Biocare). To block non-specific protein binding,
sections were treated with 3% normal goat serum and
0.05% Tween-20 (Biorad; Hercules, CA) in 1x APK buf-
fer (Ventana Medical Systems, Inc.; Tucson, AZ) for 20
minutes at ambient temperature. They were then incu-
bated with rabbit monoclonal VEGF-A (Biocare, PME
356 AA; dilution: ready to use; for 1 hour at ambient
temperature), rabbit polyclonal VEGF-R1 (Abcam,
Ab2350; dilution: 1:50; for 1 hour at ambient
temperature), and rabbit polyclonal VEGF-R2 (Abcam;
Ab2349; dilution: 1:200; at 4°C; overnight) antibodies.
Detection was carried out using the MACH4-HRP poly-
mer detection kit (Biocare), following the manufacturer’s
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found to be positive for VEGF-A, VEGF-R1, and VEGF-
R2 was used as a positive control; the same tissue, incu-
bated with an isotypic-matched antibody, was used as
the negative control. Sections were lightly counter-
stained with hematoxylin, dehydrated in graded alcohols,
cleared in xylene, and coverslipped. Images were
acquired from TMA cores or full face slides and digi-
tized using the Aperio System (Vista, CA).
Scoring of VEGF-A, VEGF-R1, and VEGF-R2 expression
VEGF-A, VEGF-R1 (cytoplasmic), and VEGF-R2 (cyto-
plasmic and nuclear) staining was scored for tumor and
normal epithelial cells using an H-score that had been
obtained by multiplying the staining intensity (graded as
0, negative; 1+, weak; 2+, moderate; and 3+, strong) by
the percentage of epithelial tumor cells with positive cyto-
plasmic or nuclear staining (0% to 100%). Stromal cell
staining was scored as 0, negative; 1+, weak; 2+ moderate;
and 3+, strong. Scoring on digitized images was per-
formed by a pathologist (Y.G.) who was blinded to all
clinical data, including treatment and patient outcome.
Because tumors may have abnormal protein expression
(upregulation or downregulation), we determined VEGF-A,
VEGF-R1, and VEGF-R2 epithelial and stromal ex-
pression levels in normal, non-neoplastic specimens
and compared them with those in IBC specimens. The
median value of the H-scores in normal breast biopsy
samples was selected as the cut-off. For statistical ana-
lysis, epithelial cells were grouped into low- (H ≤median)
or high- (H >median) expressing populations, and the
expression level in stromal cells was defined as low
(0-1+) and high (2+−3+).
Statistical analysis
The primary endpoint for this study was the associ-
ation between the expression of the three biomarkers
and BCSS and DFS; as a secondary endpoint, we com-
pared this expression with patients’ responses to endo-
crine therapy. BCSS was calculated from the date of
diagnosis, with death scored as an event and censoring
at the date of last follow-up or non-disease-related
death. The DFS interval was calculated from the date
of mastectomy to the development of first recurrence
(any recurrence, local or distant). Patients without re-
currence were censored at the time of last follow-up
or death. Chi-square and Fisher’s exact tests were used
to compare demographic and clinical-pathological data.
The Spearman test was used to determine the associ-
ation between the expression status of biomarkers (i.e.,
ER, PR, EGFR, HER2, VEGF-A, VEGF-R1, and VEGF-
R2). BCSS and DFS, defined by biomarker status and
other variables (age, LN status, tumor grade, chemo-
therapy, radiotherapy, and hormone therapy), wereplotted using Kaplan–Meier curves and compared
using the log-rank test. Variables found to be statisti-
cally significant in the univariate analyses were
included in a step-wise (multivariate) Cox model. The
multivariate models obtained for BCSS and DFS were
verified by subset analysis and backward elimination
[26]. The Cox model results were reported with hazard
ratios (HRs) and associated 95% confidence intervals
(CIs). Two-tailed P values less than 0.05 were consid-
ered statistically significant. The SAS 9.3 (SAS Inc,
Cary, NC) statistical software package we used for the
statistical analysis.Results
Clinical-pathological data
We identified 117 stage IIIB IBC cases (103 ductal, 8
lobular, 2 metaplastic, 3 micropapillary and 1 papillary
IBC) and 25 normal breast tissues who had been treated
at the PMCCC (Algiers, Algeria) [24]. For this study, we
evaluated 103 ductal IBC tissue samples. All IBC
patients had undergone neoadjuvant anthracycline-based
chemotherapy. Mastectomy was performed in 93% of
patients, and the remaining 7% died of disease before
surgery could be performed. Radiation therapy was
administered in 85% of patients. Adjuvant endocrine
therapy for ER+ patients consisted of tamoxifen and
goserelin in premenopausal women (56%) and aromatase
inhibitors in postmenopausal women (44%).VEGF-A, VEGF-R1, and VEGF-R2 protein expression in
normal and IBC samples
VEGF-A, VEGF-R1, and VEGF-R2 immunoreactivity
was observed in normal breast epithelial cells, under-
lying luminal epithelial cells, vascular endothelial cells,
and stromal fibroblasts (Figure 1A, D, and G). We found
significantly (P <0.01) lower cytoplasmic VEGF-A ex-
pression levels in IBC tumor epithelial cells than in nor-
mal breast tissues (Figure 1B and C), cytoplasmic VEGF-
R1 expression levels were slightly higher (Figure 1E and
F; P = 0.25), and cytoplasmic VEGF-R2 expression levels
were significantly higher (Figure 1H and I; P = 0.04)(Fig-
ure 1, Table 1 and Additional file 1: Figure S1: VEGF-A,
VEGF-R1, and VEGF-R2 protein expression in normal
and IBC samples). We also noted significant variations
in VEGF-A levels in the tumor stromal tissue, with low
and high expression noted in 37.9% and 62.1% of
tumors, respectively (Figure 1, Table 1). VEGF-A expres-
sion in tumor stromal elements varied, indicating that
stromal VEGF-A levels are correlated with different
tumor biologic behaviors (see Additional file 2: Table S1:
Stromal staining in normal and IBC cases). Representa-
tive examples of tumors with low and high VEGF-A
stromal expression levels are shown in Figure 1B and C.
Figure 1 Representative staining of VEGF-A (A-C), VEGF-R1 (D-F), and VEGF-R2 (G-I) in IBC and normal breast (A, D, G) samples. With
the H-score, IBC49 (B) expressed no epithelial VEGF-A but had low expression (1+) of stromal VEGF-A; IBC65 (C) was also negative for epithelial
VEGF-A but had high expression (3+) of stromal VEGF-A (indicated by arrows). IBC samples with low (E, H) and high (F-I) VEGF-R1 (E, F) and VEGF-
R2 (H, I) expression, respectively. An angiosarcoma was used as the positive (inset in D) and negative control (isotype-matched antibody; inset in
G). Slides were scanned and digitized using the Aperio digital system (Vista, CA).
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and biomarker status and clinical-pathological features
Of the clinical-pathological variables (age, size, LN, and
tumor grade) and biomarkers (ER, PR, HER2, EGFR, TN
status, VEGF-R1, and VEGF-R2) analyzed, tumor stro-
mal VEGF-A expression levels were strongly correlated
only with both epithelial and tumor stromal VEGF-R1
levels (P = 0.03 for both).
Tumor stromal VEGF-A and patient outcome
Tumor stromal VEGF-A expression was a strong prog-
nostic marker for both BCSS and DFS, as determined by
Kaplan-Meier analysis (P <0.01 for both, long-rank test;
Figure 2A, B). Because most IBC patients were negative
for epithelial VEGF-A, it was not feasible to assess its
value as a prognostic marker of patient outcome by
Kaplan-Meier analysis. These findings suggest thattumor stromal VEGF-A is of significant utility in pre-
dicting clinical outcome in IBC patients.
Tumor stromal VEGF-A status in patients with ER, PR,
HER2, and TN tumors
Given the prognostic and predictive value of ER, PR, and
HER2 status for stratifying patients for treatment, we
determined whether tumor stromal VEGF-A expression
is also a strong prognostic marker in ER+, PR+, HER2+,
and TN patients. A Kaplan-Meier survival analysis
demonstrated that high tumor stromal VEGF-A expres-
sion levels were an important prognostic factor for poor
BCSS in ER+ (Figure 3A; P <0.01) and HER2+ patients
(see Additional file 3: Figure S2: Kaplan-Meier survival
estimates of BCSS and DFS in IBC patients positive for
PR (A, B) and HER2 (C, D); P = 0.04) and of poor DFS,
regardless of ER (Figure 3B; P <0.01), PR, or HER2 status
Table 1 VEGF-A, VEGF-R1, and VEGF-R2 expression in
normal and IBC cases
Variable Normal cases (%) IBC cases (%) P**
VEGF-Ac (21,90)
Low expression 11 (52.4) 89 (98.9)
High expression 10 (47.6) 1 (1.1) <0.01
VEGF-R1c (25,96)
Low expression 13 (52.0) 36 (37.5)
High expression 12 (48.0) 60 (52.5) 0.25
VEGF-R2c* (20,97)
Low expression 12 (60.0) 32 (33.0)
High expression 8 (40.0) 65 (67.0) 0.04
VEGF-R2n (20,97)
Low expression 11 (55.0) 48 (49.5)
High expression 9 (45.0) 49 (50.5) 0.81
VEGF-As (20,103)
Low expression 0 39 (37.9)
High expression 20 (100) 64 (62.1) <0.01
VEGF-R1s (25,96)
Low expression 14 (56.0) 38 (39.6)
High expression 11 (44.0) 58 (60.4) 0.18
VEGF-R2s (20,100)
Low expression 6 (30.0) 48 (48.0)
High expression 14 (70.0) 52 (52.0) 0.22
* Letter c stands for cytoplasmic, n, nuclear and s, stromal. The numbers of
evaluated normal and IBC cases for each variable are shown as superscript in
parenthesis; **, Overall P value using Fisher’s exact test. In some cases the
tumor epithelial cells were lost during the immunoassay but the stromal
component remained and was scored. This explains the discrepancies
between the number of cases assessed for the epithelial and stromal contents.
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Therefore, tumor stromal VEGF-A expression appears to
be a predictor of clinical outcome that is independent of
these well-known epithelial markers.Figure 2 Kaplan-Meier survival estimates of BCSS (A) and DFS (B) in I
tumor stromal VEGF-A. The numbers of patients at risk of death from IBCIn patients with TN tumors, which are generally
poorly differentiated and are associated with a poor clin-
ical outcome [27], we found that high tumor stromal
VEGF-A was marginally associated with poor BCSS
(P = 0.05) but not with DFS (P = 0.15).
Tumor stromal VEGF-A status in LN- and LN+ patients
In clinical practice, the only factor that has consistently
been used to determine whether patients require aggres-
sive systemic therapy is LN status, and it is often used as
a critical predictor of disease recurrence, metastasis, and
survival in breast cancer patients [28]. As illustrated in
Figure 3, high tumor stromal VEGF-A expression was
not associated with poor BCSS and DFS in LN- patients
(Figure 3C and D), but it was strongly associated in LN+
patients (Figure 3E and F; P <0.01 for both). Of note, at
month 39, there was a 3.9- and 5.6-fold reduction in
BCSS and DFS, respectively, in LN+ patients with high
stromal VEGF-A expression levels (compare Figure 3C
with 3E and 3D with 3F). Given this strong association
with patient outcome, tumor stromal VEGF-A expres-
sion may be useful for identifying patients with LN+
tumors who require early interventions and more ag-
gressive therapies.
Tumor stromal VEGF-A status and endocrine treatment
In a subset analysis of endocrine treatment, high tumor
stromal VEGF-A was found to be a strong predictor of
poor BCSS in patients receiving tamoxifen (Figure 4A;
P = 0.02) but not in patients receiving aromatase inhibi-
tors (see Additional file 4: Figure S3A: Kaplan-Meier
survival estimates of BCSS and DFS in IBC patients trea-
ted with aromatase inhibitors with low and high stromal
VEGF-A expression levels; P = 0.07) and patients who
did not undergo endocrine therapy because of negative
hormone receptor status (Figure 4C; P = 0.07). High
tumor stromal VEGF-A levels were also a strongBC patients with low (dotted line) and high (continuous line)
are shown at 12, 24, 36, and 48 months below the x axis.
Figure 3 Kaplan-Meier survival estimates of BCSS (A, C, E) and DFS (B, D, F) in ER+ (A, B), LN- (C, D), and LN+ (E, F) IBC patients with
low (dotted line) and high (continuous line) stromal VEGF-A. At month 39, a 3.9-fold reduction in BCSS (indicated by arrow in 3E), and 5.6-
fold reduction and DFS (indicated by arrow in 3F) was observed in LN+ patients. The numbers of patients at risk of death from IBC are shown at
12, 24, 36, and 48 months below the x axis.
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fen (Figure 4B; P = 0.02) compared with in patients who
received aromatase inhibitors (see Additional file 4: Fig-
ure S3B; P = 0.11). These findings suggest that tumor
stromal VEGF-A expression is associated with tamoxifen
but not aromatase inhibitor resistance. Of note, high
VEGF-A levels were also predictive of poor DFS inpatients who did not undergo endocrine therapy
(Figure 4D; P = 0.01). If the natural history of IBC pro-
ceeds as it did in patients not treated with endocrine
therapy (Figure 4D), then tamoxifen may have exerted a
protective effect in patients with high stromal VEGF-A
levels; these patients experienced no relapses from 22 to
40 months (see Additional file 4: Figure S3C), whereas
Figure 4 Kaplan-Meier survival estimates of BCSS (A, C) and DFS (B, D) in IBC patients treated with tamoxifen (A, B) but not endocrine
therapy (C, D) with low (dotted line) and high (continuous line) stromal VEGF-A. The numbers of patients at risk of death from IBC are
shown at 12, 24, 36 and 48 months below the x axis.
Table 2 Multivariate Cox proportional hazard model
BCSS* Disease Free Survival
Variable HR (95% CI) P value HR (95% CI) P value
VEGF-As(101,103) 5.0 (2.03-12.3) <0.01 4.2 (1.7-10.3) <0.01
HER2(101, 103) 2.7 (1.07-6.8) 0.04 NS
Hormone
treatment(101,103)
NS 0.5 (0.25-1.0) 0.06
Tumor grade(101,103) NS 2.1 (0.96-4.5) 0.06
* BCSS, breast cancer-specific survival; HR, hazard ratios; CI, confident intervals;
VEGF-As, tumor stromal VEGF-A; NS, not significant. The numbers of evaluated
IBC cases are shown as superscript in parenthesis.
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experienced a steady rate of relapses during the same
period. The difference between these two groups was
not significant (P = 0.86), although this is a hypothetical
comparison given the molecular differences between the
two populations (see the Discussion section).
Multivariate analyses
We used a Cox proportional hazards model, with death
from breast cancer (median BCSS, 25.1 [range, 0.5-
53.2 months]) and time to recurrence (median DFS,
21.5 months [range, 0.5-53.2 months]) as the endpoints
and tumor grade, LN status, radiotherapy and hormone
treatment, ER/PR, HER2, EGFR, TN, VEGF-R1, VEGF-
R2, tumor stromal VEGF-A, and tumor stromal VEGF-
R1 as the predictive variables. Using a stepwise evalu-
ation, verified by backward and subset variable analyses,
we determined that tumor stromal VEGF-A expression
was the best predictor tested (Table 2). Axillary LN in-
volvement at presentation was noted in 88% of IBC
patients; however, it was not significant on multivariate
analysis. Tumor grade and hormonal treatment were notassociated with DFS (P = 0.06 for both). The significant
predictors of BCSS and DFS were tumor stromal VEGF-
A and HER2 and tumor stromal VEGF, respectively, with
tumor stromal VEGF-A being the strongest predictor of
poor BCSS (HR, 5.0; 95% CI: 2.0-12.3; P <0.01) and DFS
(HR, 4.2; 95% CI: 1.7-10.3; P <0.01).
Discussion
Bevacizumab binds to VEGF-A, blocking its biological
activity, which in turn affects the vasculature that
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behind bevacizumab use in clinical trials is that tumor
VEGF-A expression levels will determine response to
bevacizumab treatment. Clinical trials of bevacizumab in
breast cancer, including IBC, have demonstrated that
patients with high basal tumor VEGF-A expression
levels experience a response [17], but VEGF-A expres-
sion is not predictive of outcome [16,18,19]. In our
study, we found that tumor stromal VEGF-A expression
levels were a strong independent predictor of BCSS and
DFS in IBC patients; that the tumor stromal VEGF-A
level is predictive of DFS, regardless of ER, PR, HER2,
and LN status; and that treatment response to tamoxifen
(not to aromatase inhibitors) is associated with the
tumor stromal VEGF-A expression level.
Axillary LN involvement at presentation is noted in
about 55% to 85% of patients with IBC, and LN status
remains an important prognostic indicator [1,28]. How-
ever, LN was not significant in the multivariate analysis.
Similarly, in a previous study, no significant association
was found between overall survival and disease-specific
survival rates and LN status in IBC patients [30]. Although
these findings are of considerable interest and may explain
the lack of correlation between bevacizumab treatment
and VEGF-A expression, the data must be interpreted
with caution. IBC is a rare disease; to our knowledge, the
current study is the largest analysis of VEGF-A, VEGF-R1,
and VEGF-R2 expression in IBC. However, as we previ-
ously noted [24], our research has the drawbacks inherent
to retrospective studies [31]; therefore, these findings war-
rant further independent confirmation.
Various tumor models [32,33], including IBC [22],
have been used to demonstrate that the supportive net-
work provided by the stroma is critical to a cancer’s
phenotype and aggressiveness and to patient outcome.
Although the cause of high VEGF-A expression levels in
the breast tumor stroma is unknown, a significant in-
crease in human VEGF-A levels in the serum and tumor
was observed in the WIBC-9 murine xenograft, along
with a significant increase in murine VEGF-A levels [20].
Furthermore, hypoxia, a major inducer of VEGF in
tumors and a characteristic feature of IBC [34], induces
upregulation of VEGF in mammary fibroblasts [35]. This
confirms the known compensatory upregulation of host
VEGF-A [21]; on the other hand, it emphasizes the need
to completely block VEGF-A to achieve maximal tumor
growth inhibition [12,21]. Our data support the theory
that higher doses of bevacizumab are needed in IBC
patients to completely block high tumor stromal VEGF-
A expression levels and achieve optimal tumor inhib-
ition. However, this may be clinically impossible given
the observed toxic adverse events that result from the
doses currently in use [36,37]. Because of the observed
co-expression of VEGF-A and other angiogenic factors,additional targeting of other signaling pathways is
needed to achieve optimal clinical responses. Higher
levels of angiogenic factors, such as thromboxane A2 re-
ceptor, cyclooxygenase-2, angiopoietin 2, and thrombo-
modulin, and chemokines, such as stromal-derived
factor 1 and its receptor CXCR-4, have been reported in
IBC than in non-IBC patients [6,38,39]. These factors,
alone or in combination with VEGF-A, may promote
IBC’s metastatic potential. In particular, CXCR-4, which
is associated with brain metastases in IBC [40], is stimu-
lated by VEGF-A [41], linking VEGF-A expression to the
migratory potential of tumor cells. These molecules may
also be good candidates for theranostic applications, in
combination with anti-angiogenic treatments.
In a subset analysis of the efficacy of endocrine ther-
apy response in IBC patients, a high tumor stromal
VEGF-A expression level was significantly associated
with both poor BCSS and DFS in tamoxifen-treated
patients. Interestingly, tumor stromal VEGF-A expres-
sion was also significantly associated with poor DFS in
patients who did not undergo endocrine therapy. It is
impossible to draw a definitive conclusion about the role
of tumor stromal VEGF-A and tamoxifen treatment be-
cause of the lack of a subset of ER+ patients who did
not receive tamoxifen because of ethical considerations;
however, we considered patients not undergoing endo-
crine therapy because of negative ER status as an indica-
tor of the natural course of the disease. Tamoxifen
exerted a protective effect, as demonstrated by the ab-
sence of DFS events from months 22 to 40; during the
same period, a continuous decrease in survival duration
was observed in patients who did not undergo endocrine
therapy (see Additional file 4: Figure S3C). However, the
two groups differed molecularly. Further studies are
needed to determine whether stromal VEGF-A is an in-
dicator of tamoxifen resistance.
As for the mechanisms that implicate VEGF-A in tam-
oxifen response, reactive stroma and vessels may pro-
duce growth factors that stimulate tumor cells such that
tumor’s inhibitory effect on tumor growth is bypassed by
paracrine tumor growth stimulatory pathways, resulting
in high angiogenesis with hormone resistance [42]. In
addition, tumor cells, under tamoxifen pressure, may
produce growth factors that directly or indirectly stimu-
late angiogenesis. Specifically, tamoxifen induces an in-
crease in tumor growth factor β1 expression in tumor
cancer cells and stromal fibroblasts [43,44], which in
turn, can increase VEGF-A expression in both breast
tumor cells and tumor-associated macrophages [45,46].
This VEGF-A release by activated stroma may increase
the growth of ER+ malignant epithelial cells and adja-
cent normal epithelium [47]. These findings and our
data indicate that IBC patients with high tumor stromal
VEGF-A levels will not benefit from tamoxifen but may
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angiogenic treatment.Conclusions
In this study, tumor stromal VEGF-A expression was
associated with an increased risk of breast cancer death
and recurrence in IBC patients, independent of clinical-
pathological risk factors and tamoxifen treatment.
Tumor stromal VEGF-A expression levels at diagnosis
may be an effective prognostic factor that will allow
individualization of therapy. In future prospective clin-
ical trials, the prognostic power of tumor stromal VEGF-
A expression should be confirmed in IBC patients.Additional files
Additional file 1: Figure S1. VEGF-A, VEGF-R1, and VEGF-R2 protein
expression in normal (N) and IBC (I) samples. H-scores were taken as
continuous variables and plotted as relative units (RU). Significant
differences are indicated by a horizontal line with the corresponding P
value (unpaired t-tests). The letter c stands for cytoplasmic and n for
nuclear. The median H-score for normal tissues were taken as the cut-off.
VEGF-A: median, 80 (SD, 52.5; range, 0–200); VEGF-R1: median, 127.5 (SD,
89.8; range, 0–300); VEGF-R2 cytoplasmic: median, 90 (SD, 86.3; range, 0–
300); VEGF-R2 nuclear: median, 60 (SD, 55.4; range, 0–180).
Additional file 2: Table S1. Stromal staining in normal and IBC cases.
Additional file 3: Figure S2. Kaplan-Meier survival estimates of BCSS (A,
C) and DFS (B, D) in IBC patients who were positive for PR (A, B) and
HER2 (C, D), with low (dotted line) and high (continuous line) stromal
VEGF-A levels. The numbers of patients at risk of death from IBC are
shown at 12, 24, 36, and 48 months below the x axis.
Additional file 4: Figure S3. Kaplan-Meier survival estimates of BCSS (A)
and DFS (B) in IBC patients treated with aromatase inhibitors, with low
(dotted line) and high (continuous line) stromal VEGF-A levels. Figure 3C
shows the DFS survival analysis of tumor stromal VEGF-A+ patients
treated with tamoxifen (solid) and patients who did not receive
endocrine therapy. The numbers of patients at risk of death from IBC are
shown at 12, 24, 36, and 48 months below the x axis.Competing interests
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